middle.news
Nexsen adds a second GBS device as StrepSure heads for early 2027 FDA submission
8:20am on Wednesday 28th of October, 2026 AEDT
•
Healthcare
Read Story
Nexsen adds a second GBS device as StrepSure heads for early 2027 FDA submission
8:20am on Wednesday 28th of October, 2026 AEDT
Key Points
Proposed 50:50 FlashDx joint venture adds a second GBS device
StrepSure FDA submission target shifts to early 2027
Hong Kong facility becomes Nexsen’s principal Asian R&D base
New diagnostic programs target traumatic brain injury and neonatal sepsis
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Nexsen (ASX:NXN)
OPEN ARTICLE